Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

In-Person Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026
Seoul
NEW EPISODE
ADT Intensification: The Evidence You Can’t Afford to Miss
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®
ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Case: Implementing ADT Intensification in mHSPC
Case: Implementing ADT Intensification in mHSPC
MinuteCE®
Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
EHA 2026: Long-Term Zanubrutinib Outcomes
EHA 2026: Long-Term Zanubrutinib Outcomes
Oncology and Hematology
EHA 2026: Long-Term Zanubrutinib Outcomes
Alessandra Tedeschi, MD
- Alessandra Tedeschi, MD
NEW EPISODE
De Novo mHSPC: Recognizing the Patients Who Need More
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®
De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Oncology and Hematology
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
- Chan Y. Cheah, MBBS
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Oncology and Hematology
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Nicolas Girard, MD; Louise Lim, MD
- Nicolas Girard, MD
- Louise Lim, MD
- Jacob Sands, MD
- Stephanie McDonald, MSN, FNP-BC, AOCNP
Addressing Oncology-Related Infertility Through Collaborative Care
Addressing Oncology-Related Infertility Through Collaborative Care
Clinician's Roundtable
Addressing Oncology-Related Infertility Through Collaborative Care
Irene Su, MD, MSCE
- Irene Su, MD, MSCE

Medical News

$talquetamab and daratumumab in relapsed or refractory myeloma$ $talquetamab and daratumumab in relapsed or refractory myeloma$
Medical News
Talquetamab and Daratumumab in Relapsed or Refractory Myeloma
06/18/2026
Read more
Medical News
Olaparib Plus Radium-223 Improves rPFS in COMRADE
06/18/2026
Read more
Medical News
Text Messaging and FIT Completion in a Quality Improvement Trial
06/18/2026
Read more
Medical News
PORTEC-4a Trial Reports Molecular Profile Guided Adjuvant Treatment
06/17/2026
Read more

CME/CE

NEW EPISODE
Targeting PTEN: Why It Matters
Targeting PTEN: Why It Matters
MinuteCE®
Targeting PTEN: Why It Matters
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
NEW EPISODE
Molecular Profiling in mHSPC: Informing Treatment Selection
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®
Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits

Clinical Practice

Post-BCMA Treatment Selection in R/R Multiple Myeloma
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Project Oncology®
Post-BCMA Treatment Selection in R/R Multiple Myeloma
Steve Jackson, PharmD; Nisha Joseph, MD
- Steve Jackson, PharmD
- Nisha Joseph, MD
NEW EPISODE
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS; Mary-Ellen Taplin, MD
1.00 program credit
- Scott T. Tagawa, MD, MS
- Mary-Ellen Taplin, MD
1.00 program credit
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- Tiffany Traina, MD, FASCO

Programs

SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP; Andrew E. Hendifar, MD
- Brian P. McDonough, MD, FAAFP
- Andrew E. Hendifar, MD
Key Differences in Pulmonary and Extrapulmonary NEC Management
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS; Lowell B. Anthony, MD, FACP
- Alexandria May, PharmD, BCPS
- Lowell B. Anthony, MD, FACP